Can a low-fat meal ease stomach side effects of NF1 tumor drug?

NCT ID NCT05101148

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether taking selumetinib with a low-fat meal reduces stomach problems in teenagers with neurofibromatosis type 1 (NF1) who have tumors that cannot be removed by surgery. About 24 teens will take the drug under both fed and fasted conditions to compare drug levels and side effects. The goal is to find the best way to take selumetinib to keep it working while being easier on the stomach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibromatosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS TYPE 1

Contacts and locations

Locations

Research Site

Rochester, Minnesota, 55905, United States
Research Site

Akron, Ohio, 44308, United States
Research Site

Bydgoszcz, 85-094, Poland
Research Site

Gdansk, 80-952, Poland
Research Site

Warsaw, 02-091, Poland
Research Site

Moscow, 119620, Russia
Research Site

Moscow, 125412, Russia
Research Site

Barcelona, 08950, Spain
Research Site

Madrid, 28009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.